Alpha 2.0
Login Register
» Authors » M Domine Gomez

M Domine Gomez

Explore the profile of M Domine Gomez including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 3
Citations 111
Followers 0
Related Specialty
Oncology
Top 10 Co-Authors
M Thomas
M Reck
C Britschgi
B Wittig
M Provencio
T Csoszi
J Kollmeier
R J Hoyer
A Lowczak
J M Weiss
Published In
Ann Oncol
Clin Transl Oncol
Lung Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial
Soo R, Vervita K, Fruh M, Cho B, Majem M, Rodriguez Abreu D, et al.
Lung Cancer . 2025 Mar; 202:108454. PMID: 40023017
Background: ABC-lung explores the potential effect of combining atezolizumab and bevacizumab with either carboplatin/paclitaxel (ABCPac) or pemetrexed (ABPem) in patients with EGFR-mutant NSCLC, resistant to tyrosine kinase inhibitors (TKIs). Methods:...
2.
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
Weiss J, Csoszi T, Maglakelidze M, Hoyer R, Beck J, Domine Gomez M, et al.
Ann Oncol . 2019 Sep; 30(10):1613-1621. PMID: 31504118
Background: Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HSPC) causes multi-lineage myelosuppression. Trilaciclib is an intravenous CDK4/6 inhibitor in development to proactively preserve HSPC and immune system function during...
3.
Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study
Thomas M, Ponce-Aix S, Navarro A, Riera-Knorrenschild J, Schmidt M, Wiegert E, et al.
Ann Oncol . 2018 Aug; 29(10):2076-2084. PMID: 30137193
Background: The immune surveillance reactivator lefitolimod (MGN1703), a DNA-based TLR9 agonist, might foster innate and adaptive immune response and thus improve immune-mediated control of residual cancer disease. The IMPULSE phase...
4.
SEOM clinical guidelines for the treatment of small-cell lung cancer 2013
Domine Gomez M, Moran Bueno T, Artal Cortes A, Remon Masip J, Lianes Barragan P
Clin Transl Oncol . 2013 Sep; 15(12):985-90. PMID: 24005836
In this updated SCLC guidelines the authors have reviewed the "SEOM recommendation" for diagnosis and treatment of patients, including consideration for elderly and unfit patients. We hope the SCLC guidelines...